Drug intelligence / Profile preview

PreserVision AREDS3

Development stage: Unknown
Lead developer: Bausch + Lomb
Modality: Small Molecules
Administration: Oral

Overview

PreserVision AREDS3 is a triple-action nutritional supplement developed by Bausch + Lomb specifically for the management and risk reduction of age-related macular degeneration (AMD). This advanced formulation builds upon the clinically validated AREDS2 regimen—comprising vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper—by incorporating a complex of eight B vitamins. The supplement is designed to support macular health, promote healthy cellular eye function and metabolism, maintain healthy homocysteine levels, and bolster the body's natural response to oxidative stress. It is delivered as a softgel and is marketed as the most advanced formula in the AREDS brand portfolio, intended to reduce the risk of moderate-to-advanced AMD progression.

Brand names: PreserVision AREDS3

Beyond the preview

Go deeper on PreserVision AREDS3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreserVision AREDS3.

Explore the full profile